Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

• In 2022, diagnosed prevalence of Neuroendocrine tumors will reach to 689,000 cases across the 16 countries covered in the publisher's epidemiology forecast.
• There are eight leading marketed drugs for the treatment of Neuroendocrine tumors. Pfizer, Novartis, and Hutchison are key players in the disease space.
• R&D activity in Neuroendocrine tumors space is considerable globally, with 11 products in Phase III development.
• Academic sponsors dominate clinical trial development in Neuroendocrine tumors, with Germany emerging as the key country for conducting late-stage clinical trials in Neuroendocrine tumors.
• Deals involving strategic alliances of Neuroendocrine tumors assets are the most common type globally.
• No commercial launch is expected for Neuroendocrine tumors in the next 18 months.

Scope

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Neuroendocrine tumors market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine tumors market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.